Holen Sie sich die Stockscreener-App
31.01
3.16%
0.95
Handel nachbörslich:
32.00
0.99
+3.19%
Schlusskurs vom Vortag:
$30.06
Offen:
$30.97
24-Stunden-Volumen:
740.82K
Relative Volume:
0.96
Marktkapitalisierung:
$3.57B
Einnahmen:
$22.50M
Nettoeinkommen (Verlust:
$-203.82M
KGV:
-17.75
EPS:
-1.7469
Netto-Cashflow:
$-148.03M
1W Leistung:
+5.33%
1M Leistung:
-11.43%
6M Leistung:
+17.95%
1J Leistung:
+32.46%
1-Tages-Spanne:
$30.52
$32.04
1-Wochen-Bereich:
$28.81
$32.04
52-Wochen-Spanne:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
31.01 | 3.46B | 22.50M | -203.82M | -148.03M | -1.7469 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Behavioral Patterns of NAMSW and Institutional Flows - Stock Traders Daily
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
A cholesterol pill's kidney and safety data head to a major heart meeting - Stock Titan
JPMorgan Chase & Co. Trims Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Earnings Update: How does NewAmsterdam Pharma Company NV Equity Warrant compare to its peersGap Up & Long Hold Capital Preservation Plans - baoquankhu1.vn
Does NewAmsterdam Pharma Company NV have declining or rising EPSEarnings Beat & AI Forecasted Stock Moves - baoquankhu1.vn
NAMS SEC FilingsNewAmsterdam Pharma Company N.V 10-K, 10-Q, 8-K Forms - Stock Titan
(NAMS) Risk Channels and Responsive Allocation - Stock Traders Daily
Why is NewAmsterdam Pharma Company NV stock going downIPO Watch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Truist initiates NewAmsterdam Pharma stock coverage with buy rating By Investing.com - Investing.com South Africa
Truist initiates NewAmsterdam Pharma stock coverage with buy rating - Investing.com
Published on: 2026-03-19 02:35:41 - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Fcpm Iii Services B.V. - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS is Decheng Capital LLC's 5th Largest Position - MarketBeat
ArrowMark Colorado Holdings LLC Has $8.85 Million Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
(NAMSW) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Gains Report: Why is NewAmsterdam Pharma Company NV stock going down2026 Spike Watch & Daily Technical Stock Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $1,357,309.98 in Stock - MarketBeat
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NewAmsterdam Pharma Director Sells Shares - TradingView
Director at NewAmsterdam Pharma (NAMS) sells 44,619 shares - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
Warrant exercise and trust sale at NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc. - MarketBeat
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma (NAMS) director exercises 44,619 warrants as trust sells 28,186 shares - Stock Titan
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock - MarketBeat
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
(NAMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Trend Report: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullishMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma gives two new hires 10K options, 2,200 RSUs - Stock Titan
Proposed NAMS share sales reported via Form 144 (NAMS) - Stock Titan
Stock Recap: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2025 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - Defense World
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):